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Summary 
One hundred and eight patients with non-smaU cell lung cancer were treated in a Phase II trial with MGBG 
at a dose of 600 mg/m 2 i.v. weekly. Partial responses were noted in 3/43 patients with adenocarcinoma and 
1/40 with squamous cell carcinoma. No  responses were noted in 24 patients with large cell carcinoma. 
Overall, the drug was reasonably well-tolerated. At this dosage and schedule, MGBG has no substantial an- 
titumor activity for patients with non-small cell lung cancer. 
Introduction 
Methyl-glyoxal-bis-guanylhydrazone (MGBG) was 
first described by Freedlander in 1958 as having in 
vitro antitumor activity (1). The mechanism of  ac- 
tion of  the drug is thought to be related to inhibi- 
tion of  the enzyme S-adenosyl methionine (SAM) 
decarboxylase which catalyzes synthesis of  spermi- 
dine (2). MGBG in concentrations as low as 0.5 
micrograms/ml is a potent inhibitor of  spermidine 
biosynthesis (3, 4, 5). At concentrations of 2 to 8 
pM ( 0 . 6 - 2 . 4  micrograms/ml),  MGBG appears to 
act selectively on polymine synthesis. At concen- 
trations as high as 100/~M (30 micrograms/ml) or 
more, the drug has other direct toxic effects, in- 
cluding inhibition of  protein synthesis (4) and com- 
plete inhibition of  mitochondrial respiration (5). 
There is evidence to suggest that spermidine is of 
importance in the initiation of DNA synthesis and 
that MGBG-mediated depression of DNA synthe- 
sis is associated with spermidine depletion ( 6 - 8 ) .  
Responses to MGBG in clinical trials were first 
noted in acute myelocytic leukemia (9 - 11). Other 
clinical studies have noted responses in carcinoma 
of the breast, renal carcinoma, lymphoma, colon 
carcinoma, pancreatic carcinoma, and carcinoma 
of  the esophagus and bladder ( 1 2 -  18). Since there 
are no known single agents with high order of  ac- 
tivity in non-small carcinoma of the lung, the 
Southwest Oncology (SWOG) conducted a phase 
II trial of  MGBG in this disease entity. 
Materials and methods 
From twenty member institutions of the Southwest 
Oncology Group, 108 patients were entered into a 
study of  the efficacy of  MGBG in extensive non- 
small cell carcinoma of  the lung. Extensive disease 
is defined as measurable disease outside of one 
hemithorax. Of these 108 patients, two were in- 
eligible because of  poor  performance status (both 
Address for reprints: Southwest Oncology Group (SWOG-8003), Operations Office, 4450 Medical Drive, San Antonio, TX 78229, 
U.S.A. 
90 
patients had a performance status of  4). Of the 106 
remaining patients, two were judged inevaluable 
because of insufficient data, whereas 15 were con- 
sidered evaluable for toxicity, but not for re- 
sponse. Of these 15 partially evaluable cases, 9 in- 
curred an early death (within two weeks of  study 
entry), three refused further therapy before three 
drug doses were administered, one was lost to fol- 
low-up after one drug course, one had an inade- 
quate trial because of toxicity, and one progressed 
after two drug courses rather than the outlined 
three courses. 
Of the 106 eligible cases, 43 (41~ had squa- 
mous cell carcinoma, 51 (48~ had adenocarci- 
noma, and 12 (11%) had large cell anaplastic car- 
cinoma by diagnosis of the institutional patholog- 
ist. Males comprised 77~ of the patient popula- 
tion. All had measurable disease and a performan- 
ce status of  at least 2 (50% or greater Karnofsky 
rating). Each patient had a WBC count greater 
than 3,000/mm 3, platelets greater than 100,000/ 
mm 3, BUN less than 20 mg0/0, creatinine less than 
1.2 mg%, bilirubin less than 2 mg%, and no clini- 
cal or chemical evidence of biliary obstruction. A 
majority (55070) of  eligible patients had received no 
prior chemotherapy. 
An initial dose of  MGBG of  600 mg/m z was 
given intravenously in DsW or normal saline over 
no less than 30 min into a freely running I.V. line. 
Drug dosages were governed by hematologic toxi- 
city. MGBG was given weekly, providing the WBC 
count was greater than 3,000/mm 3 and the platelet 
count was greater than 100,000/mm 3. An adequate 
trial for therapy consisted of three courses of treat- 
ment. The administration of  MGBG was held if 
the WBC count dropped into the range of 2 , 000 -  
2,999/mm 3 or if the platelets fell between 75,000 - 
99,999/m 3. Upon recovery, the same dosage was 
resumed. If the WBC count fell below 2,000/m 3 
and /or  the platelets below 75,000/m 3, MGBG was 
not administered until counts recovered into the 
pre-treatment range. At this point, the dosage was 
decreased by 100 mg/m 2. For patients who had 
received prior chemotherapy or radiotherapy, four 
weeks were required to have elapsed since that 
therapy. 
Gastrointestinal and neuromuscular toxicity also 
determined therapy. No course of  MGBG was 
given until stomatitis had resolved from the pre- 
vious course of therapy. After recovery, the next 
dose of MGBG was decreased by 100 mg/m 2 for 
severe stomatitis. Patients with mild to moderate 
diarrhea and /or  nausea and vomiting were manag- 
ed symptomatically. Patients with moderately 
severe diarrhea or nausea and vomiting (grade 3) 
had the drug withheld until symptoms abated and 
then received a 200 mg/m 2 dose reduction. Patients 
with mild or transient paresthesias received the 
same dose of MGBG or 100 mg/m 2 reduction in 
dosage if the paresthesia was severe or continual. 
Patients with any muscle weakness or pain had 
CPK, aldolase, and, when feasible, EMG studies 
performed. MGBG administration was withheld 
until symptoms of  weakness or pain subsided. 
When symptoms had completely abated, reinstitu- 
tion of the drug was begun at a 200 mg/m 2 reduc- 
tion. 
Therapeutic responses were defined as follows: 
complete remission (CR) - the disappearance 
of all evidence of disease for greater than one 
month; 
partial remission (PR) - a greater than 50~ de- 
crease in the sum of  the products of the perpendi- 
cular diameters of  all measured lesions with no 
simultaneous increase in the size of any lesion or 
the appearance of  new lesions for at least four 
weeks; 
stable disease-objective tumor regression not 
qualifying for partial remission but lasting at least 
four weeks, or a steady state not qualifying for in- 
creasing disease of at least eight weeks duration; 
increasing disease-unequivocal increase of at 
least 25~ in the size of any measured lesions or the 
appearance of any new lesion. 
Results 
Adverse effects 
The toxic effects of MGBG in this study confirmed 
previous reports using this drug ( 9 -  11, 19). Speci- 
fically, the main toxic effects consisted mostly of  
weakness (33 patients of whom 11 had severe toxi- 
Table 1. Type and degree of  toxicity 
91 
MGBG 
None Mild Mod.  Sev. Fatal 
Granulocytopenia 104 1 1 
Thrombocytopenia  (platelet) 103 2 1 
Anemia  99 1 5 1 
Leukopenia (WBC) 102 2 1 1 
Peripheral neuropathy 73 7 15 11 
Dizziness/hot  flashes 102 1 3 
Diarrhea 95 8 2 1 
Weight loss 91 7 6 2 
Nausea /vomi t ing /anorexia  67 14 12 14 
GI (other) 105 1 
Allergy/rash/epidermit is  102 2 2 
Cardiac (hypotension) 105 1 
Cardiac (other) 104 1 1 
Hematur ia  105 1 
Mucosi t is /ulcers/s tomati t is  93 5 5 3 
Venous sclerosis/phlebitis 105 1 
Other 105 1 
Table 2. Responses according to cell type 
Cell type CR PR Stable N R / I N C  Unknown  
Squamous cell 
Prior XR T 
No 0 1 9 8 3 
Yes 0 0 11 11 0 
Prior Chemo 
No 0 0 12 12 1 
Yes 0 1 8 7 2 
Large cell 
Prior XR T 
No 0 0 2 3 1 
Yes 0 0 1 4 1 
Prior Chemo 
No 0 0 2 3 0 
Yes 0 0 1 4 2 
Adenocarcinoma 
Prior XR T 
No 0 2 7 12 4 
Yes 0 1 9 12 4 
Prior Chemo 
No 0 2 13 9 5 
Yes 0 1 3 15 3 
city) and nausea and vomiting (40 patients of 
whom 14 had severe symptoms). Other toxic ef- 
fects included weight loss (15 patients), mucositis 
and stomatitis (13 patients), and diarrhea (11 pa- 
tients). (The complete list of adverse effects can be 
seen in Table 1.) 
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Response 
There were no complete remissions and four par- 
tial remissions in the group. Table 2 shows that 
three patients of the four responders were adeno- 
carcinomas (3/43=7%) and the remaining re- 
sponder was squamous cell carcinoma (1/40= 
2.5%) for an overall response rate of 4.5% (4/93) 
in the evaluable group. The comparison among the 
three cell types did not show any significant dif- 
ference (p = 0.393). There were, in addition, thirty- 
nine patients (41.9%) with stable disease in the 
study. The patients who received no prior 
chemotherapy had median survivals of twenty-two 
weeks while those patients who were previously 
treated had median survivals of ten weeks (p = 
0.113). There was no difference in survival be- 
tween male and female patients. 
Discussion 
Eighty-nine patients with non-small cell carcinoma 
of the lung were adequately treated with MGBG. 
The drug was generally well-tolerated. Weakness, 
nausea and vomiting, weight loss, and mucositis 
and stomatitis were the most often observed side 
effects. 
There were four partial remissions reported 
(4/93 =4.3%). Three of the four responders had 
histologically proven adenocarcinoma with the re- 
maining responder having squamous cell carci- 
noma. Thirty-nine patients exhibited stable disease 
(39/93 = 41.9%). Two of the four responders had 
received no prior chemotherapy. It is, therefore, 
our conclusion that at this specific dose level and 
frequency of administration, MGBG did not show 
adequate activity in any histologic cell type of the 
non-small cell variety. Furthermore, we do not feel 
that further investigation of the drug as a single 
agent in non-small cell carcinoma of the lung is 
warranted. 
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